Schmid H P
Urologische Universitätsklinik, Inselspital, Bern.
Ther Umsch. 1998 Jul;55(7):426-8.
Based on its exclusive organspecificity, prostate specific antigen (PSA) holds a key role in diagnosis and follow up of prostatic carcinoma. for intermediate PSA levels of 4-10 ng/mL, differentiation from benign prostatic hyperplasia is difficult and the indication for biopsy must be judged individually. Basically, diagnosis is only indicated in those patients, in whom there are therapeutic consequences. The same is true for the use of PSA in follow up after therapy. Further measures should be based on the symptoms of the patient rather than on a laboratory value.
基于其独特的器官特异性，前列腺特异性抗原（PSA）在前列腺癌的诊断和随访中起着关键作用。对于4 - 10 ng/mL的中等PSA水平，很难与良性前列腺增生相鉴别，活检指征必须个体化判断。基本上，只有在那些会产生治疗后果的患者中才进行诊断。PSA在治疗后随访中的应用也是如此。进一步的措施应基于患者的症状而非实验室值。
